Trial Profile
Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults at 18 Years of Age or Above: a Randomised, Open-label, Parallel-controlled Clinical Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 12 Aug 2022 Planned End Date changed from 1 May 2022 to 30 Dec 2022.
- 12 Aug 2022 Planned primary completion date to 13 Aug 2022.
- 12 Aug 2022 Status changed from recruiting to active, no longer recruiting.